TCT-143 Prognostic Implications of Anemia in Impella-Supported HRPCI: Insights From the cVAD PROTECT III Study

摘要: BackgroundAnemia is prevalent among patients with cardiovascular disease and is associated with adverse outcomes. However, data regarding the impact of anemia in high-risk percutaneous coronary intervention (HRPCI) are limited.MethodsPatients undergoing Impella-supported HRPCI in the prospective multicenter cVAD PROTECT III study were assessed for anemia based on baseline hemoglobin levels according to the World Health Organization criteria. Patients were stratified into one of 3 groups (no anemia, mild anemia, and moderate or severe anemia). Major adverse cardiovascular and cerebrovascular events (MACCE: defined as all-cause death, myocardial infarction, stroke/transient ischemic attack, and repeated revascularization) at 30 and 90 days, and major bleeding events were analyzed based on baseline anemia status.ResultsOf 1,072 patients, 62.0%(n= 665) had baseline anemia, with 18.7 …